PCNA and breast carcinoma: The results of this exploratory study indicate that high numbers of PCNA+ TAMs, particularly in the absence of an anti-tumor immune microenvironment (as indicated by a low Tc/ClassII signature score), are associated with poor outcomes in breast cancer patients treated with neoadjuvant chemotherapy.